HiFiBiO Therapeutics

HiFiBiO Therapeutics is a clinical-stage global biotech pioneering a unique high-resolution translational solution (DIS, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS combines unique single-cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases driving a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS approach. HiFiBiO Therapeutics is headquartered in Cambridge, MA with additional operations in Paris, France, Hong Kong, Shanghai, and...

Microfluidics,single-cell,antibodies,therapeutics,drug discovery,target discovery,biomarker discovery,artificial intelligence,machine learning,and immune modulation

Hifibio therapeutics operates in the Biotechnology industry.

Hifibio therapeutics's revenue is 11m - 100m

Hifibio therapeutics has 51 - 200 employees.